+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies



Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies



Antiviral Therapy 12(4 Pt B): 639-650



The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055737751

Download citation: RISBibTeXText

PMID: 17944271


Related references

Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. Journal of Virology 81(16): 8722-8729, 2007

Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). Journal of Biological Chemistry 291(17): 9218-9232, 2016

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proceedings of the National Academy of Sciences of the United States of America 102(22): 7988-7993, 2005

The ADP-ribose-1''-monophosphatase domains of severe acute respiratory syndrome coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses. Journal of General Virology 92(Pt 8): 1899-1905, 2011

Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. Journal of Virology 82(1): 588-592, 2008

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proceedings of the National Academy of Sciences of the United States of America 102(33): 11876-11881, 2005

Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. Journal of Virology 87(14): 8017-8028, 2013

Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro. Chinese Medical Journal 118(6): 493-496, 2005

Current status of antiviral severe acute respiratory syndrome coronavirus research. 2007

Recent Developments in the Virology and Antiviral Research of Severe Acute Respiratory Syndrome Coronavirus. Infectious Disorders - Drug Targets 7(1): 29-41, 2007

Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus. Infectious Disorders Drug Targets 7(1): 29-41, 2007

Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrobial Agents and ChemoTherapy 59(1): 206-216, 2016

Three dimensional model of severe acute respiratory syndrome coronavirus helicase ATPase catalytic domain and molecular design of severe acute respiratory syndrome coronavirus helicase inhibitors. Journal of Computer-Aided Molecular Design 20(5): 305-319, 2006

Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Medicinal Research Reviews 26(4): 414-433, 2006

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. Journal of Virology 78(20): 11334-9, 2004